secwatch.observer — SEC 8-K summary
======================================

Issuer:     Petros Pharmaceuticals, Inc. (PTPI)
CIK:        0001815903
Form:       8-K
Filed at:   2022-04-04T23:59:59+00:00
Accession:  0001104659-22-042215
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Petros Pharma reports 2021 net sales $7.8M, net loss down 56% to $9.0M
----------------------------------------------------------------------

- Net sales $7.8M vs $9.6M in 2020; prescription sales fell to $4.6M due to competitive coupons.
- Gross profit up 13% to $6.2M on lower write-offs and fulfillment costs; SG&A flat at $15.6M.
- Net loss improved to $9.0M from $20.6M, largely from reduced fair value derivative liability.
- Cash at year-end ~$24M; pursuing OTC switch for STENDRA with two self-selection studies launched.
- Collaboration with Dr. Drew Pinsky to raise men's health awareness; H100 Peyronie's license expanded.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815903/000110465922042215/0001104659-22-042215-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815903/000110465922042215/tm2211512d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-042215

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer